Positive Initial Data Announced from Ph 1 MINOTAUR Trial of Lunresertib in Combination with FOLFIRI
“The initial results from the ongoing MINOTAUR trial demonstrate promising efficacy and tolerability data of lunresertib plus FOLFIRI in genomically defined tumors that represent 20% of all gastrointestinal cancers,” said Dr. Elisa Fontana. “These early data suggest that lunresertib plus FOLFIRI combination therapy may effectively treat patients with CCNE1 amplification and deleterious FBXW7 mutations, who often suffer from poor prognosis and lack approved treatment options. We are excited by the prolonged benefit that some patients continue to experience on therapy, especially in colorectal cancer, and the favorable tolerability of this lunresertib combination therapy across tumor types, unlike other agents combined with irinotecan.”
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
